Valeant Recalls Diltiazem HCl Capsules for Dissolution Failures
Valeant Pharmaceuticals is recalling 23,884 bottles of Diltiazem HCl CD capsules because they failed dissolution specifications, potentially affecting drug release.
What this means for you
Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.
Our severity reasoning: The FDA classified this recall as Class III, which the rubric defines as typically resulting in a score of 1 or 2 because it is unlikely to cause adverse health consequences.
Plain-English summary
Valeant Pharmaceuticals North America LLC is recalling 23,884 bottles of Diltiazem HCl CD capsules, 360 mg, 90-count bottles. The product is prescription-only and was manufactured for Oceanside Pharmaceuticals, a division of Valeant Pharmaceuticals North America LLC. The specific lots affected are 18J035P, 18K094P, and 18K093P, all with an expiration date of 09/2020.
The recall was initiated because the capsules failed dissolution specifications. This means the amount of drug released at certain time points was higher than the allowed limits. The affected products were distributed nationwide in the USA and Puerto Rico.
Consumers and healthcare providers should stop using the recalled Diltiazem HCl CD capsules and contact their healthcare provider for guidance on alternative treatment options. The FDA has classified this recall as Class III, indicating that use of or exposure to the violative product is not likely to cause adverse health consequences.
The recalled product
- Product
- Diltiazem HCl CD capsules, 360 mg, 90-count bottles, Rx Only, Manufactured for: Oceanside Pharmaceuticals, a division of Valeant Pharmaceuticals North America LLC, Bridgewater, NJ 08807 USA; By: Valeant Pharmaceuticals International, Inc., Steinbach, MB R5G 1Z7 Canada; NDC 68682-
- Manufacturer
- Valeant Pharmaceuticals North America LLC
- Category
- Drug — Cardiovascular
- Hazard
- Affected units
- 23,884
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Lots: 18J035P
- 18K094P
- 18K093P
- Exp 09/2020
Distribution
Part of a larger recall action
This product is one of 5 recalled by Valeant Pharmaceuticals North America LLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 5 products in this recall →Related recalls
Same manufacturer · Valeant Pharmaceuticals North America LLC
See all →- ModerateValeant Recalls Cardizem CD Capsules for Dissolution Failures
FDA (Drugs) · 2019-02-20
- ModerateValeant Recalls Cardizem CD Capsules for Dissolution Failures
FDA (Drugs) · 2019-02-20
- ModerateValeant Recalls Cardizem CD Capsules for Dissolution Failures
FDA (Drugs) · 2019-02-20
- ModerateValeant Recalls Cardizem CD Capsules for Dissolution Failures
FDA (Drugs) · 2019-02-20
- ModerateValeant Recalls Cortaid 12-Hour Anti-itch Cream Due to cGMP Deviations
FDA (Drugs) · 2018-10-31
Same hazard · dissolution failure
See all →- ModerateApotex Recalls Paxil Tablets for Failed Dissolution and Stability Testing
FDA (Drugs) · 2026-09-02
- ModerateMylan Recalls Acamprosate Calcium Tablets Due to Dissolution Failure
FDA (Drugs) · 2026-08-26
- ModerateChlorthalidone 25mg tablets failed dissolution specifications in two batches
FDA (Drugs) · 2026-06-24
- ModerateNiacin extended-release tablets failed dissolution testing at 24 hours
FDA (Drugs) · 2026-06-17
- ModerateMinocycline extended-release tablets failed dissolution testing during stability analysis
FDA (Drugs) · 2026-06-17